Literature DB >> 23225173

How do we improve patient compliance and adherence to long-term statin therapy?

Patricia Maningat1, Bruce R Gordon, Jan L Breslow.   

Abstract

Statins are highly effective drugs prescribed to millions of people to lower LDL-cholesterol and decrease cardiovascular risk. The benefits of statin therapy seen in randomized clinical trials will only be replicated in real-life if patients adhere to the prescribed treatment regimen. But, about half of patients discontinue statin therapy within the first year, and adherence decreases with time. Patient, physician and healthcare system-related factors play a role in this problem. Recent studies have focused more on the patients' perspectives on non-adherence. Adverse events are cited as the most common cause of statin discontinuation; thus, the healthcare provider must be willing to ally and dialogue with patients to address concerns and assess the risks and benefits of continued statin therapy.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23225173      PMCID: PMC3534845          DOI: 10.1007/s11883-012-0291-7

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN: 1523-3804            Impact factor:   5.113


  71 in total

Review 1.  Standards of medical care in diabetes--2012.

Authors: 
Journal:  Diabetes Care       Date:  2012-01       Impact factor: 19.112

2.  Physician follow-up and provider continuity are associated with long-term medication adherence: a study of the dynamics of statin use.

Authors:  M Alan Brookhart; Amanda R Patrick; Sebastian Schneeweiss; Jerry Avorn; Colin Dormuth; William Shrank; Boris L G van Wijk; Suzanne M Cadarette; Claire F Canning; Daniel H Solomon
Journal:  Arch Intern Med       Date:  2007-04-23

3.  Impact of fixed-dose and multi-pill combination dyslipidemia therapies on medication adherence and the economic burden of sub-optimal adherence.

Authors:  Sanjeev Balu; Robert J Simko; Ralph M Quimbo; Mark J Cziraky
Journal:  Curr Med Res Opin       Date:  2009-11       Impact factor: 2.580

4.  Influence of the use of functional foods enriched with phytosterols/-stanols on adherence to statin therapy.

Authors:  Simone R B M Eussen; Marcel L Bouvy; Cathy J M Rompelberg; Menno E van der Elst; Johan Garssen; Marco H Oosterveld; Anthonius de Boer; Johan J de Gier; Henk J van Kranen; Olaf H Klungel
Journal:  Pharmacoepidemiol Drug Saf       Date:  2011-06-07       Impact factor: 2.890

5.  The implications of therapeutic complexity on adherence to cardiovascular medications.

Authors:  Niteesh K Choudhry; Michael A Fischer; Jerry Avorn; Joshua N Liberman; Sebastian Schneeweiss; Juliana Pakes; Troyen A Brennan; William H Shrank
Journal:  Arch Intern Med       Date:  2011-05-09

Review 6.  Predictors of nonadherence to statins: a systematic review and meta-analysis.

Authors:  Devin M Mann; Mark Woodward; Paul Muntner; Louise Falzon; Ian Kronish
Journal:  Ann Pharmacother       Date:  2010-08-11       Impact factor: 3.154

7.  Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TEXCAPS): additional perspectives on tolerability of long-term treatment with lovastatin.

Authors:  J R Downs; M Clearfield; H A Tyroler; E J Whitney; W Kruyer; A Langendorfer; V Zagrebelsky; S Weis; D R Shapiro; P A Beere; A M Gotto
Journal:  Am J Cardiol       Date:  2001-05-01       Impact factor: 2.778

Review 8.  Lipid screening and cardiovascular health in childhood.

Authors:  Stephen R Daniels; Frank R Greer
Journal:  Pediatrics       Date:  2008-07       Impact factor: 7.124

9.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.

Authors:  J Shepherd; S M Cobbe; I Ford; C G Isles; A R Lorimer; P W MacFarlane; J H McKillop; C J Packard
Journal:  N Engl J Med       Date:  1995-11-16       Impact factor: 91.245

Review 10.  Medication adherence: its importance in cardiovascular outcomes.

Authors:  P Michael Ho; Chris L Bryson; John S Rumsfeld
Journal:  Circulation       Date:  2009-06-16       Impact factor: 29.690

View more
  58 in total

Review 1.  Cholesterol-lowering drugs: science and marketing.

Authors:  Livio Garattini; Anna Padula
Journal:  J R Soc Med       Date:  2017-01-13       Impact factor: 5.344

2.  Time course, outcome and management of adverse drug reactions associated with metformin from patient's perspective: a prospective, observational cohort study in the Netherlands.

Authors:  Loek de Jong; Linda Härmark; Eugène van Puijenbroek
Journal:  Eur J Clin Pharmacol       Date:  2016-02-11       Impact factor: 2.953

3.  Value of a Hypothetical Pharmacogenomic Test for the Diagnosis of Statin-Induced Myopathy in Patients at High Cardiovascular Risk.

Authors:  Dominic Mitchell; Jason R Guertin; Jacques LeLorier
Journal:  Mol Diagn Ther       Date:  2018-12       Impact factor: 4.074

4.  Predictors of first-year nonadherence and discontinuation of statins among older adults: a retrospective cohort study.

Authors:  Richard Ofori-Asenso; Jenni Ilomäki; Mark Tacey; Si Si; Andrea J Curtis; Ella Zomer; J Simon Bell; Sophia Zoungas; Danny Liew
Journal:  Br J Clin Pharmacol       Date:  2018-11-08       Impact factor: 4.335

5.  A Discrete Event Simulation Model to Assess the Economic Value of a Hypothetical Pharmacogenomics Test for Statin-Induced Myopathy in Patients Initiating a Statin in Secondary Cardiovascular Prevention.

Authors:  Dominic Mitchell; Jason R Guertin; Anick Dubois; Marie-Pierre Dubé; Jean-Claude Tardif; Ange Christelle Iliza; Fiorella Fanton-Aita; Alexis Matteau; Jacques LeLorier
Journal:  Mol Diagn Ther       Date:  2018-04       Impact factor: 4.074

Review 6.  Why maximum tolerated dose?

Authors:  Hans G Stampfer; Genevieve M Gabb; Simon B Dimmitt
Journal:  Br J Clin Pharmacol       Date:  2019-07-22       Impact factor: 4.335

7.  Moderating Effects of Patient Characteristics on the Impact of Financial Incentives.

Authors:  Meredith B Rosenthal; Andrea B Troxel; Kevin G Volpp; Walter F Stewart; Thomas D Sequist; James B Jones; AnneMarie G Hirsch; Karen Hoffer; Jingsan Zhu; Wenli Wang; Amanda Hodlofski; Darra Finnerty; Jack J Huang; David A Asch
Journal:  Med Care Res Rev       Date:  2017-05-08       Impact factor: 3.929

8.  Vaccine against PCSK9: the natural strategy from passive to active immunization for the prevention of atherosclerosis.

Authors:  Fernando Civeira; Estíbaliz Jarauta
Journal:  J Thorac Dis       Date:  2017-11       Impact factor: 2.895

9.  Increasing Prescription Length Could Cut Cardiovascular Disease Burden And Produce Savings In South Africa.

Authors:  Thomas Gaziano; Sylvia Cho; Stephen Sy; Ankur Pandya; Naomi S Levitt; Krisela Steyn
Journal:  Health Aff (Millwood)       Date:  2015-09       Impact factor: 6.301

10.  Perspective on the 2013 American Heart Association/American College of Cardiology guideline for the use of statins in primary prevention of low-risk individuals.

Authors:  Jan L Breslow
Journal:  Circ Res       Date:  2014-02-28       Impact factor: 17.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.